Key result
Management strategies for atrial fibrillation are evolving, with digoxin playing a subsidiary role for rate control and safety concerns raised regarding quinidine therapy.
Answers are grounded in this paper and cite their sources.
This review highlights the evolving management of atrial fibrillation, emphasizing the subsidiary role of digoxin and safety concerns with quinidine.
Management strategies for the most common sustained cardiac arrhythmia,¹,²atrial fibrillation, have undergone considerable evolution over the last several years. The objectives of therapy are to slow ventricular rate and restore and maintain sinus rhythm. Prevention of symptoms and reduction in the risk of complications such as stroke are therapeutic goals with agents that slow atrioventricular nodal conduction, antiarrhythmic agents, and anticoagulants. The utility of digoxin for rate control has been questioned with recent studies suggesting that this former mainstay of therapy may now play a subsidiary role.³β-Blockers and calcium channel blockers are now frequently used for slowing ventricular response. Concerns regarding the safety of quinidine have been raised by a recent meta-analysis showing an increased mortality in patients randomized to quinidine therapy or placebo for atrial fibrillation,⁴although there are many limitations to this retrospective analysis. These safety concerns have been extended with recent observations
No takes yet. Share an insight, caveat, or question.
N.A. Mark Estes (1992) conducted a review in Atrial Fibrillation. Management strategies (digoxin, beta-blockers, calcium channel blockers, quinidine) was evaluated. Management strategies for atrial fibrillation are evolving, with digoxin playing a subsidiary role for rate control and safety concerns raised regarding quinidine therapy.
Synapse has enriched 10 related papers. Consider them for comparative context: